This is an international site for AFINITOR® (everolimus) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country

I am a healthcare professional outside of the US I am a US Resident I am a patient outside of the US

Afinitor Logo

Novartis Logo

Safety Information
Afinitor International Website | For International Healthcare Professionals Only | US Residents

EUROPEAN SUMMARY OF PRODUCT

CHARACTERISTICS

Find out more about the product characteristics for AFINITOR

FOR YOUR PATIENTS

Find out more about the patient Information

MOA VIDEO

Watch an animation demonstrating AFINITOR's Mechanism of Action
AFINITOR is indicated for the treatment of unresectable or metastatic, well-or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

Disclaimer: This is an international website for AFINITOR® (everolimus) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
NovartisOncology.com | About Novartis Oncology | Site Map | Contact Us
Use of website is governed by the Terms of Use and Privacy Policy
© Novartis AG